Pharmaceutical Technology
JULY 5, 2024
Fucaso, a BCMA CAR T-cell therapy, is co-developed by Innovent and IASO Bio and was approved to treat multiple myeloma in China last month.
Pharma Times
JULY 5, 2024
The neurodegenerative disease currently affects more than 200,000 people worldwide
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JULY 5, 2024
BioSenic and Medsenic filed patent application with the USPTO to extend the protection for the use of arsenic trioxide (ATO) for sepsis.
Pharma Times
JULY 5, 2024
Pneumococcus is the leading cause of pneumonia, meningitis and sepsis worldwide
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Pharmaceutical Technology
JULY 5, 2024
The UK life science industry is crossing its fingers as a Labour government takes the reigns following 14 years of Conservative rule.
pharmaphorum
JULY 5, 2024
Discover how innovative approaches and specialised expertise in peptide API synthesis are increasing efficiency and driving advancements in the manufacturing of Active Pharmaceutical Ingredients (API).
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
pharmaphorum
JULY 5, 2024
Explore the vital partnerships and people involved in shaping Labour's policies on the NHS, healthcare, and life sciences during the general election. Learn more about the key areas of focus and priorities.
Pharmaceutical Technology
JULY 5, 2024
The EMA has validated Philogen and Sun Pharmaceutical’s marketing authorisation application (MAA) for Nidlegy, a treatment for melanoma.
pharmaphorum
JULY 5, 2024
Reports indicate that private equity firms Bain Capital and Cinven may be contemplating a bid for the consumer health division of Sanofi.
Pharmaceutical Technology
JULY 5, 2024
The UK took to the polls on 4 July 2024 and voted in a new government. How will a Labour government look for the clinical trial sector?
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
pharmaphorum
JULY 5, 2024
After Labour landslide in UK general election, former shadow health secretary West Streeting sets out his objectives for the NHS.
Pharmaceutical Technology
JULY 5, 2024
Whilst Regeneron and Sanofi secured approval in Europe for COPD, the FDA has delayed Dupixent’s application review for the disease in the US.
pharmaphorum
JULY 5, 2024
Learn about Professor Melanie Bailey's research on single-cell multi-omics and its oncological potential through the company SEISMIC. Discover the groundbreaking work and contributions to the field.
Pharmaceutical Technology
JULY 5, 2024
As the UK transitions into a Labour party government, the pharma industry urges for boosted investment and talent attraction.
Outsourcing Pharma
JULY 5, 2024
Meg Wilkinson, a resilient cancer survivor, recently sat down with OSP editor Liza Laws to discuss her journey from diagnosis to founding the Omentum Project.
Pharmaceutical Technology
JULY 5, 2024
CAN-3110 is under clinical development by Candel Therapeutics and currently in Phase I for High-Grade Glioma.
Drug Patent Watch
JULY 5, 2024
This chart shows the drugs with the most patents in Denmark. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.
Pharmaceutical Technology
JULY 5, 2024
CTX-310 is under clinical development by CRISPR Therapeutics and currently in Phase II for Hypertriglyceridemia.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Drug Patent Watch
JULY 5, 2024
Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd Iii, and Boehringer Ingelheim and, and is included in five NDAs.
Pharmaceutical Technology
JULY 5, 2024
CTX-310 is under clinical development by CRISPR Therapeutics and currently in Phase II for Heterozygous familial hypercholesterolemia (heFH).
Drug Patent Watch
JULY 5, 2024
Annual Drug Patent Expirations for ORILISSA Orilissa is a drug marketed by Abbvie and is included in one NDA. It is available from one supplier. There are ten patents protecting this drug.
Pharmaceutical Technology
JULY 5, 2024
CTX-310 is under clinical development by CRISPR Therapeutics and currently in Phase II for Homozygous Familial Hypercholesterolemia (HoFH).
Drug Patent Watch
JULY 5, 2024
Annual Drug Patent Expirations for LILETTA Liletta is a drug marketed by Medicines360 and is included in one NDA. It is available from one supplier. There are three patents protecting this drug.
Pharmaceutical Technology
JULY 5, 2024
AZD-2389 is under clinical development by AstraZeneca and currently in Phase I for Metabolic Dysfunction-Associated Steatohepatitis (MASH).
Drug Patent Watch
JULY 5, 2024
Annual Drug Patent Expirations for QINLOCK Qinlock is a drug marketed by Deciphera Pharms and is included in one NDA. It is available from one supplier.
Pharmaceutical Technology
JULY 5, 2024
NN-6561 is under clinical development by Novo Nordisk and currently in Phase I for Metabolic Dysfunction-Associated Steatohepatitis (MASH).
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Trialfacts
JULY 5, 2024
Contents About the Study Why Participate? Your Rights Who Can Participate? More Study Details About the Research Center Research Center: The University of Arizona College of Nursing Location: This virtual study is open to the United States Lead Researchers: Chris Segrin, PhD and Terry Badger, PhD, RN IRB: This study has been reviewed and approved by the University of Arizona Institutional Review Board An Institutional Review Board responsible for human subjects research at The University of Ariz
Pharmaceutical Technology
JULY 5, 2024
Dalfampridine IR is under clinical development by Solaxa and currently in Phase II for Spinocerebellar Ataxia (SCA).
Pharmaceutical Commerce
JULY 5, 2024
An observational, retrospective cohort study undergoes this investigation in individuals 24 years of age or older.
Pharmaceutical Technology
JULY 5, 2024
ICTCAR-028 is under clinical development by Innovative Cellular Therapeutics and currently in Phase III for Hematological Tumor.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Expert insights. Personalized for you.
244 
Let's personalize your content